Published in Prostate on September 01, 2008
Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28
Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res (2009) 2.27
A compendium of genome-wide associations for cancer: critical synopsis and reappraisal. J Natl Cancer Inst (2010) 2.00
Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate (2009) 1.99
Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate (2009) 1.95
Genome-wide association study (GWAS)-identified disease risk alleles do not compromise human longevity. Proc Natl Acad Sci U S A (2010) 1.60
Associations Between iCOGS Single Nucleotide Polymorphisms and Upgrading in Both Surgical and Active Surveillance Cohorts of Men with Prostate Cancer. Eur Urol (2015) 1.47
New developments in the medical management of prostate cancer. Mayo Clin Proc (2010) 1.41
An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis. PLoS One (2011) 1.30
Prostate cancer in young men: an important clinical entity. Nat Rev Urol (2014) 1.15
Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers? Genome Med (2010) 1.09
Genetic prostate cancer risk assessment: common variants in 9 genomic regions are associated with cumulative risk. J Urol (2010) 1.08
The role of the BRCA2 gene in susceptibility to prostate cancer revisited. Cancer Epidemiol Biomarkers Prev (2008) 1.03
Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies. J Urol (2013) 0.98
Identifying association model for single-nucleotide polymorphisms of ORAI1 gene for breast cancer. Cancer Cell Int (2014) 0.96
Pathological outcomes associated with the 17q prostate cancer risk variants. J Urol (2009) 0.94
Prostate cancer risk alleles are associated with prostate cancer volume and prostate size. J Urol (2013) 0.90
The burden of prostate cancer in Canada. Can Urol Assoc J (2009) 0.90
Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer. J Urol (2011) 0.87
Number of prostate cancer risk alleles may identify possibly 'insignificant' disease. BJU Int (2010) 0.82
Clinical validity and utility of genetic risk scores in prostate cancer. Asian J Androl (2016) 0.82
Assessing interactions of two loci (rs4242382 and rs10486567) in familial prostate cancer: statistical evaluation of epistasis. PLoS One (2014) 0.79
Associations of ChREBP and Global DNA Methylation with Genetic and Environmental Factors in Chinese Healthy Adults. PLoS One (2016) 0.78
Single nucleotide polymorphisms and prostate cancer susceptibility. Rev Urol (2008) 0.78
Multigene panels in prostate cancer risk assessment: a systematic review. Genet Med (2015) 0.75
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature (2007) 144.95
A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet (2007) 52.68
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet (2007) 14.37
A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 13.47
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol (2005) 12.31
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
Staging prostate cancer. Microsc Res Tech (2000) 1.20
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Resolving individuals contributing trace amounts of DNA to highly complex mixtures using high-density SNP genotyping microarrays. PLoS Genet (2008) 20.38
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 13.47
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet (2008) 7.14
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med (2014) 6.89
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst (2006) 6.02
NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw (2010) 5.98
Prostate cancer. N Engl J Med (2003) 5.91
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science (2013) 4.71
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 4.20
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer (2004) 4.10
Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med (2012) 3.92
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet (2002) 3.87
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Recent developments in genomewide association scans: a workshop summary and review. Am J Hum Genet (2005) 3.76
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76